A new trial activated at MDACC classic.clinicaltrials.gov/ct2/show/NCT05… A novel MET TKI (ABN401) for METex14 NSCLC pts. Preliminary efficacy ORR 75% in TKI-naive pts and very favorable toxicity profile. Lauren Averett Byers, MD @esinghimd METCrusaders Exon 20 Group, a multi-stakeholder organization

OUT NOW‼️ The FINAL OncoAlert 🚨NewsLetter of 2023 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅Differential tx effect in younger🆚older👵👴 ✅Liquid Biopsy🧬response evaluation criteria ✅Targeting🎯 ERBB2 in #NSCLC 🫁 ✅FDA🇺🇸approval Olaparib &

The authors evaluated the clinicopathologic/genomic characteristics of ERBB2-amplified #NSCLC & explored HER2 ADC therapy. High-level ERBB2 amplification reliably predicts HER2 overexpression in NSCLC patients - HER2 ADC is effective therapy for NSCLC pts. bit.ly/3HzP9rS

Please join us in our upcoming webinar on RET fusion testing! IASLC CAPathologists USCAP RET Renegades RETpositive

Christopher Fletcher, MD, Dana-Farber has received the #AACR24 James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research for discoveries transforming the cancer pathology field and establishing innovative therapies. ms.spr.ly/6017c4cES